еНаука - преглед

Преглед према Аутор Ciuleanu, Tudor E

Приказ резултата 1 до 5 од 5
ГодинаНасловАутор(и)Тип резултатаМп-кат.
2020Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group AnalysisCufer, Tanja; Ciuleanu, Tudor E; Berzinec, Peter; Galffy, Gabriela; Jakopovic, Marko; Jassem, Jacek; Jovanovic, Dragana D; Mihaylova, Zhasmina; Ostoros, Gyula; Thallinger, Christiane;
Zemanova, Milada; Zielinski, Christoph;
Научни чланак
21M21 - Рад у врхунском међ. часопису
2015Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trialThatcher, Nick; Hirsch, Fred R; Luft, Alexander V; Szczesna, Aleksandra; Ciuleanu, Tudor E; Dediu, Mircea; Ramlau, Rodryg; Galiulin, Rinat K; Bálint, Beatrix; Losonczy, György;
Kazarnowicz, Andrzej; Park, Keunchil; Schumann, Christian; Reck, Martin; Depenbrock, Henrik; Nanda, Shivani; Kruljac-Letunic, Anamarija; Kurek, Raffael; Paz-Ares, Luis; Socinski, Mark A;
Научни чланак
21aM21a - Рад у међ. часопису изузетних вредности
2017Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel in Advanced Non-Small Cell Lung Cancer (GALAXY-2)Pillai, Rathi N; Fennell, Dean; Kovcin, Vladimir N; Ciuleanu, Tudor E; Ramlau, Rodryg; Kowalski, Dariusz; Schenker, Michael; Perin, Branislav M; Yalcin, Ilker; Teofilovici, Florentina;
Vukovic, Vojo M; Ramalingam, Suresh S;
Конференцијски рад
Мп категорија ће бити приказана накнадно.
2010Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.Ciuleanu, Tudor E; Samarzjia, M; Demidchik, Y; Beliakouski, V; Rancic, M; Bentsion, DL; Orlov, SV; Schaeffier, BA; De, Jager RL; Breitz, HBКонференцијски рад
Мп категорија ће бити приказана накнадно.
2020Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non?Small-Cell Lung Cancer (GALAXY-2)Pillai, Rathi N; Fennell, Dean A; Kovcin, Vladimir N; Ciuleanu, Tudor E; Ramlau, Rodryg; Kowalski, Dariusz; Schenker, Michael; Yalcin, Ilker; Teofilovici, Florentina; Vukovic, Vojo M;
Ramalingam, Suresh S;
Научни чланак
21aM21a - Рад у међ. часопису изузетних вредности